{"nctId":"NCT00867490","briefTitle":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","startDateStruct":{"date":"2009-03"},"conditions":["Hypertension"],"count":186,"armGroups":[{"label":"Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine","type":"EXPERIMENTAL","interventionNames":["Drug: Candesartan+HCTZ - Phase 1","Drug: Aliskiren+HCTZ - Phase 2","Drug: Aliskiren+HCTZ+amlodipine - Phase 3"]}],"interventions":[{"name":"Candesartan+HCTZ - Phase 1","otherNames":[]},{"name":"Aliskiren+HCTZ - Phase 2","otherNames":[]},{"name":"Aliskiren+HCTZ+amlodipine - Phase 3","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for Core Study:\n\n\\- Patients with mean sitting diastolic blood pressure ≥ 100 mmHg and \\< 110 mmHg\n\nInclusion criteria for the Extension:\n\n\\- msSBP ≥ 140 mm Hg and/or msDBP ≥ 90 mm Hg at Visit 5 of the core study\n\nExclusion Criteria for Core Study:\n\n* Patients with mean diastolic blood pressure ≥ 110 mmHg or mean systolic blood pressure ≥ 180 mmHg\n* Patients with prior stroke, hypertensive encephalopathy or heart attack\n* Patients with type 1 diabetes mellitus\n* Patients with type 2 diabetes mellitus with poor glucose control\n\nExclusion criteria for the Extension:\n\n* Premature discontinuation in the core study or failure to comply with the core study protocol\n* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures, known or suspected contraindications to diuretics as described in the SmPC (particularly amlodipine 5 mg), e.g. severe hypotension, shock - including cardiogenic shock, obstructions impairing the flow out of the left ventricle (e.g. significant aortic stenosis)\n* Any patient that the investigator decides should not participate in the extension study for medical reasons\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.81","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Pressure During the Core Phase of the Study","description":"Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Rate During the Core Phase of the Study","description":"Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study","description":"Normalized blood pressure was defined as a msSBP \\< 140 mmHg and/or a msDBP \\< 90 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study","description":"Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Pressure During the Extension Phase of the Study","description":"Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Rate During the Extension Phase of the Study","description":"Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study","description":"Normalized was defined as a msSBP \\< 140 mm Hg and/or a msDBP \\< 90 mm Hg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study","description":"Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":186},"commonTop":[]}}}